Premium
A mechanistic rationale for the investigation of sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article ‘Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial’
Author(s) -
Pabel Steffen,
Hamdani Nazha,
Sossalla Samuel
Publication year - 2021
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.2091
Subject(s) - empagliflozin , medicine , heart failure with preserved ejection fraction , heart failure , cardiology , ejection fraction , diastole , clinical trial , diabetes mellitus , type 2 diabetes , blood pressure , endocrinology